Scaffolds for blocking protein-protein interactions.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Current Topics in Medicinal Chemistry

• Publication date

  2007-05-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/156802607780906726PMID 17508924
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Design and modular parallel synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhibitor scaffold.

  2006cited by this paper
• Synthesis and biological evaluation of leucine enkephalin turn mimetics.

  2006cited by this paper
• Diphenylindane-based proteomimetics reproduce the projection of the i, i+3, i+4, and i+7 residues on an alpha-helix.

  2006cited by this paper
• Targeting protein–protein interactions by rational design: mimicry of protein surfaces

  2006cited by this paper
• A light-activated beta-turn scaffold within a somatostatin analog: NMR structure and biological activity.

  2006cited by this paper
• Rapid synthesis and in situ screening of potent HIV-1 protease dimerization inhibitors.

  2006cited by this paper
• Miniature Protein Inhibitors of the p53–hDM2 Interaction

  2006cited by this paper
• Probing the structural requirements of peptoids that inhibit HDM2-p53 interactions.

  2006cited by this paper
• Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formation.

  2006cited by this paper
• Substituted 1,4‐Benzodiazepine‐2,5‐diones as α‐Helix Mimetic Antagonists of the HDM2‐p53 Protein–Protein Interaction

  2006cited by this paper
• @-Tide-stabilized beta-hairpins.

  2005cited by this paper
• Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction.

  2005cited by this paper
• Inhibiting protein-protein interactions using designed molecules.

  2005cited by this paper
• Increasing the kinase specificity of k252a by protein surface recognition.

  2005cited by this paper
• Inhibiting HIV fusion with a beta-peptide foldamer.

  2005cited by this paper
• Switching between allosteric and dimerization inhibition of HIV-1 protease.

  2005cited by this paper
• Paralog-selective ligands for bcl-2 proteins.

  2005cited by this paper
• Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction.

  2005cited by this paper
• Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL.

  2005cited by this paper
• Simple, helical peptoid analogs of lung surfactant protein B.

  2005cited by this paper
• Chimeric (alpha/beta + alpha)-peptide ligands for the BH3-recognition cleft of Bcl-XL: critical role of the molecular scaffold in protein surface recognition.

  2005cited by this paper
• Binding mode and transcriptional activation potential of high affinity ligands for the CBP KIX domain.

  2005cited by this paper
• 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR.

  2005cited by this paper
• Strategies for targeting protein-protein interactions with synthetic agents.

  2005cited by this paper
• Synthesis of a 2,3';6',3''-terpyridine scaffold as an alpha-helix mimetic.

  2005cited by this paper
• New constrained "molecular tongs" designed to dissociate HIV-1 protease dimer.

  2004cited by this paper
• High affinity, paralog-specific recognition of the Mena EVH1 domain by a miniature protein.

  2004cited by this paper
• Use of “Tethering” for the Identification of a Small Molecule that Binds to a Dynamic Hot Spot on the Interleukin‐2 Surface

  2004cited by this paper
• Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein.

  2004cited by this paper
• Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix

  2004cited by this paper
• Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach.

  2004cited by this paper
• Syntheses and activities of new C10 beta-turn peptidomimetics.

  2004cited by this paper
• Thioether side chain cyclization for helical peptide formation: inhibitors of estrogen receptor-coactivator interactions.

  2004cited by this paper
• Beta-strand mimetics.

  2004cited by this paper
• Designed calix[8]arene-based ligands for selective tryptase surface recognition.

  2004cited by this paper
• Binding proteins from alternative scaffolds.

  2004cited by this paper
• Helical peptoid mimics of magainin-2 amide.

  2003cited by this paper
• Design of beta-turn based therapeutic agents.

  2003cited by this paper
• Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex.

  2003cited by this paper
• Small molecule inhibition of hepatitis C virus E2 binding to CD81.

  2003cited by this paper
• Structural background of cyclodextrin-protein interactions.

  2003cited by this paper
• A selective irreversible inhibitor targeting a PDZ protein interaction domain.

  2003cited by this paper
• Miniature homeodomains: high specificity without an N-terminal arm.

  2003cited by this paper
• Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes

  2003cited by this paper
• Modulation of protein-protein interactions with small organic molecules.

  2003cited by this paper
• Novel selective inhibitors of the interaction of individual nuclear hormone receptors with a mutually shared steroid receptor coactivator 2.

  2003cited by this paper
• An alpha helix conformationally restricted peptide is recognized by cervical carcinoma patients' sera.

  2003cited by this paper
• Protein surface recognition by rational design: nanomolar ligands for potassium channels.

  2003cited by this paper
• Tetrabiphenylporphyrin-based receptors for protein surfaces show sub-nanomolar affinity and enhance unfolding.

  2003cited by this paper
• Mimicry of bioactive peptides via non-natural, sequence-specific peptidomimetic oligomers.

  2002cited by this paper
• Unraveling hot spots in binding interfaces: progress and challenges.

  2002cited by this paper
• Toward the synthesis of artificial proteins: the discovery of an amphiphilic helical peptoid assembly.

  2002cited by this paper
• Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion.

  2002cited by this paper
• An improved method for the synthesis of dissymmetric N,N'-disubstituted imidazole-4,5-dicarboxamides.

  2002cited by this paper
• Design, synthesis, and application of peptide secondary structure mimetics.

  2002cited by this paper
• Short constrained peptides that inhibit HIV-1 entry

  2002cited by this paper
• Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry.

  2002cited by this paper
• Mimetics of the peptide beta-strand.

  2002cited by this paper
• "@-Tides": the 1,2-dihydro-3(6H)-pyridinone unit as a beta-strand mimic.

  2002cited by this paper
• Inhibition of protein-protein association by small molecules: approaches and progress.

  2002cited by this paper
• Disruption of protein-protein interactions: design of a synthetic receptor that blocks the binding of cytochrome c to cytochrome c peroxidase.

  2001cited by this paper
• Concerted evolution of structure and function in a miniature protein.

  2001cited by this paper
• Peptoid oligomers with alpha-chiral, aromatic side chains: sequence requirements for the formation of stable peptoid helices.

  2001cited by this paper
• Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an alpha-helix.

  2001cited by this paper
• Conformational selection of inhibitors and substrates by proteolytic enzymes: implications for drug design and polypeptide processing.

  2000cited by this paper
• Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice

  2000cited by this paper
• Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis.

  2000cited by this paper
• Protein surface recognition by synthetic receptors based on a tetraphenylporphyrin scaffold.

  2000cited by this paper
• Improving SH3 domain ligand selectivity using a non-natural scaffold.

  2000cited by this paper
• Design, synthesis, and evaluation of a pyrrolinone-based matrix metalloprotease inhibitor.

  2000cited by this paper
• Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy

  2000cited by this paper
• A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry.

  2000cited by this paper
• Selective disruption of protein aggregation by cyclodextrin dimers.

  2000cited by this paper
• A designed peptidomimetic agonistic ligand of TrkA nerve growth factor receptors.

  2000cited by this paper
• Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein.

  1999cited by this paper
• Design, synthesis, and evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease dimerization.

  1999cited by this paper
• Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.

  1999cited by this paper
• Synthesis and Biological Evaluation of a Cyclo-β-tetrapeptide as a Somatostatin Analogue.

  1999cited by this paper
• Anatomy of hot spots in protein interfaces.

  1998cited by this paper
• Design strategies for the construction of independently folded polypeptide motifs.

  1998cited by this paper
• Exploiting the basis of proline recognition by SH3 and WW domains: design of N-substituted inhibitors.

  1998cited by this paper
• Highly selective mechanism-based thrombin inhibitors: structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes.

  1998cited by this paper
• Sequence-specific polypeptoids: a diverse family of heteropolymers with stable secondary structure.

  1998cited by this paper
• Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.

  1998cited by this paper
• Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins.

  1997cited by this paper
• Potent and selective thrombin inhibitors incorporating the constrained arginine mimic l-3-piperidyl(N-guanidino)alanine at P1.

  1996cited by this paper
• Nonpeptidic inhibitors of human leukocyte elastase. 3. Design, synthesis, X-ray crystallographic analysis, and structure-activity relationships for a series of orally active 3-amino-6-phenylpyridin-2-one trifluoromethyl ketones.

  1994cited by this paper
• Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.

  1994cited by this paper
• Human immunodeficiency virus gp120 binding C'C" ridge of CD4 domain 1 is also involved in interaction with class II major histocompatibility complex molecules.

  1992cited by this paper
• Turns in peptides and proteins.

  1985cited by this paper
• Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

  1983cited by this paper

• Generation of the intramolecular hydrogen bonding of a parallel β-sheet nucleated by a rigid bimetallic ring

  2026cites this paper
• Paraisariamides: Cycloheptapeptide Toxins from Entomopathogenic Fungi (Paraisaria spp.) That Inhibit Total Protein Synthesis

  2025cites this paper
• Current Computational Methods for Protein-Peptide Complex Structure Prediction.

  2023cites this paper
• Developing Small-Molecule Inhibitors of Protein-Protein Interactions Involved in Viral Entry as Potential Antivirals for COVID-19

  2022cites this paper
• Broad-Spectrum Small-Molecule Inhibitors of the SARS-CoV-2 Spike—ACE2 Protein–Protein Interaction from a Chemical Space of Privileged Protein Binders

  2022cites this paper
• Antibacterial and antiviral metabolites from cyanobacteria: Their application and their impact on human health

  2021cites this paper
• Methylene Blue Inhibits the SARS-CoV-2 Spike–ACE2 Protein-Protein Interaction–a Mechanism that can Contribute to its Antiviral Activity Against COVID-19

  2021cites this paper
• Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein–Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2

  2021cites this paper
• Small-Molecule In Vitro Inhibitors of the Coronavirus Spike – ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2

  2020cites this paper
• Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.

  2018cites this paper
• Small-Molecule Inhibitors of the CD40-CD40L Costimulatory Protein-Protein Interaction.

  2017cites this paper
• Privileged Substructures to Modulate Protein-Protein Interactions

  2017cites this paper
• TNF superfamily protein-protein interactions: feasibility of small- molecule modulation.

  2015cites this paper
• Small-Molecule Probes for the Modulation of Ligand-Receptor Interactions within the TNF Superfamily

  2015cites this paper
• Anti-infective Natural Products from Cyanobacteria

  2015cites this paper
• Chapter 5 Chemogenomics with Protein Secondary-Structure Mimetics

  2015cites this paper
• Direct targeting of Arabidopsis cysteine synthase complexes with synthetic polypeptides to selectively deregulate cysteine synthesis.

  2013cites this paper
• Efficient Synthesis of Thiolactoside Glycoclusters by Ruthenium‐Catalyzed Cycloaddition Reaction of Disubstituted Alkynes on Carbohydrate Scaffolds

  2013cites this paper
• Computational peptidology: a new and promising approach to therapeutic peptide design.

  2013cites this paper
• Ester vs. amide on folding: a case study with a 2-residue synthetic peptide.

  2013cites this paper
• Interplay between protein order, disorder and oligomericity in receptor signaling.

  2012cites this paper
• New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors.

  2012cites this paper
• Synthesis and conformational studies of peptido-squaramide foldable modules: a new class of turn-mimetic compounds.

  2012cites this paper
• One-pot synthesis of poly-substituted tetramic acids for the preparation of putative turn mimics

  2012cites this paper
• Supramolecular Approaches for Inhibition of Protein–Protein and Protein–DNA Interactions

  2012cites this paper
• Recognition of exterior protein surfaces using artificial ligands based on calixarenes, crown ethers, and tetraphenylporphyrins

  2012cites this paper
• A leap into the chemical space of protein-protein interaction inhibitors.

  2012cites this paper
• Natural products and Pharma 2011: strategic changes spur new opportunities.

  2011cites this paper
• Uncoupled binding and folding of immune signaling-related intrinsically disordered proteins.

  2011cites this paper
• Druggability assessment of protein-protein interfaces.

  2011cites this paper
• Influencing uptake and localization of aminoglycoside-functionalized peptoids.

  2011cites this paper
• Modulators of protein-protein interactions: novel approaches in targeting protein kinases and other pharmaceutically relevant biomolecules.

  2011cites this paper
• A nonpeptidic reverse-turn scaffold stabilized by urea-based dual intramolecular hydrogen bonding.

  2011cites this paper
• Non-peptidic α-helical mimetics as protein-protein interaction inhibitors.

  2011cites this paper
• Functionalizable oligoprolines as molecular scaffolds.

  2011cites this paper
• Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease.

  2011cites this paper
• Discovery of modulators of protein-protein interactions: current approaches and limitations.

  2011cites this paper
• Rational design of small-molecule inhibitors of protein-protein interactions: Application to the oncogenic c-Myc/Max interaction

  2011cites this paper
• Predicting and characterising protein-protein complexes

  2011cites this paper
• Recent Advances in β‐Strand Mimetics

  2011cites this paper
• Enzyme inhibition by allosteric capture of an inactive conformation.

  2011cites this paper
• Novel pyrrolopyrimidine-based α-helix mimetics: cell-permeable inhibitors of protein−protein interactions.

  2011cites this paper
• Design, synthesis, and validation of a β-turn mimetic library targeting protein-protein and peptide-receptor interactions.

  2011cites this paper
• SPECIAL FOCUS: THE ROLE OF TRANSMEMBRANE DOMAINS IN ADHESION

  2010cites this paper
• The SCHOOL of nature: III. From mechanistic understanding to novel therapies.

  2010influential citation
• The SCHOOL of nature: II. Protein order, disorder and oligomericity in transmembrane signaling.

  2010cites this paper
• Protein intrinsic disorder and oligomericity in cell signaling.

  2010cites this paper
• Parallel synthesis of an oligomeric imidazole-4,5-dicarboxamide library.

  2010cites this paper
• Targeting protein-protein interactions: a promising avenue of anti-HIV drug discovery.

  2010cites this paper
• The SCHOOL of nature: I. Transmembrane signaling.

  2010cites this paper
• Exploring the molecular design of protein interaction sites with molecular dynamics simulations and free energy calculations.

  2009cites this paper
• Combinatorial Synthesis, Sequencing, and Biological Applications of Peptide and Peptidomimetic Libraries

  2009cites this paper
• Architecture, function and prediction of long signal peptides

  2009cites this paper
• Targeting protein-protein interactions for therapeutic intervention: a challenge for the future.

  2009cites this paper
• Small-molecule costimulatory blockade: organic dye inhibitors of the CD40–CD154 interaction

  2009cites this paper
• Organic dyes as small molecule protein–protein interaction inhibitors for the CD40–CD154 costimulatory interaction

  2009cites this paper
• Protease dimer formation disrupted.

  2009cites this paper
• Knitting and untying the protein network: Modulation of protein ensembles as a therapeutic strategy

  2008cites this paper
• Peptoid architectures: elaboration, actuation, and application.

  2008cites this paper
• Novel mechanistic concept of platelet inhibition

  2008cites this paper
• Crystal structure of the yeast eIF4A-eIF4G complex: An RNA-helicase controlled by protein–protein interactions

  2008cites this paper
• In silico-in vitro screening of protein-protein interactions: towards the next generation of therapeutics.

  2008cites this paper
• Targets Looking for Drugs: A Multistep Computational Protocol for the Development of Structure-Based Pharmacophores and Their Applications for Hit Discovery

  2008cites this paper
• Binding to protein surfaces by supramolecular multivalent scaffolds.

  2008cites this paper
• Small-molecule inhibitors of protein-protein interactions.

  2008cites this paper
• alpha-Helix mimetics as inhibitors of protein-protein interactions.

  2008cites this paper
• SCHOOL Model and New Targeting Strategies

  2008cites this paper
• Delineation of functional roles of parasite-specific inserts in the malarial S-adenosylmethionine decarboxylase / ornithine decarboxylase

  2008cites this paper
• Drugging the "undruggable".

  2006cites this paper
• Chemogenomics with protein secondary-structure mimetics.

  2003cites this paper